Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Protocol: 
AAAR6417
Phase: 
III

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Are you Eligible? (Inclusion Criteria)

1. Patients must have metastatic breast cancer. There is no limit for number
of doses of HER-2 targeted therapy prior to registration.
2. Patients must be at increased risk for cardiotoxicity.
3. Patients must not have taken within 21 days prior to Step 1 Registration,
be currently taking at the time of Step 1 Registration, or planning to take
once registered to Step 1 a beta blocker, ARB, or ACE inhibitor.
4. Patients currently taking a beta blocker, ARB, or ACE inhibitor at the
time
of Step 1 Registration are eligible to register for the non-randomized
observational cohort (Arm 3).
5. Patients must be 18 years of age or older.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States